A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
PubMed
25986943
DOI
10.1136/gutjnl-2015-309197
PII: gutjnl-2015-309197
Knihovny.cz E-zdroje
- Klíčová slova
- GASTRIC CANCER, HELICOBACTER PYLORI,
- MeSH
- antibakteriální látky terapeutické užití MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- Helicobacter pylori * MeSH
- infekce vyvolané Helicobacter pylori komplikace diagnóza farmakoterapie MeSH
- kombinovaná farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- metronidazol terapeutické užití MeSH
- nádory žaludku mikrobiologie prevence a kontrola MeSH
- prospektivní studie MeSH
- protivředové látky terapeutické užití MeSH
- tetracyklin terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Geografické názvy
- Čína MeSH
- Názvy látek
- antibakteriální látky MeSH
- metronidazol MeSH
- protivředové látky MeSH
- tetracyklin MeSH
OBJECTIVE: To clarify the full range of benefits and adverse consequences of Helicobacter pylori eradication as a strategy for gastric cancer prevention, the community-based intervention trial was launched in Linqu County, China. DESIGN: A total of 184,786 residents aged 25-54 years were enrolled in this trial and received (13)C-urea breath test. H. pylori positive participants were assigned into two groups, either receiving a 10-day quadruple anti-H. pylori treatment or lookalike placebos together with a single dosage of omeprazole and bismuth. RESULTS: The prevalence of H. pylori in trial participants was 57.6%. A total of 94,101 subjects completed the treatment. The overall H. pylori eradication rate was 72.9% in the active group. Gender, body mass index, history of stomach disease, baseline delta over baseline-value of (13)C-urea breath test, missed medication doses, smoking and drinking were independent predictors of eradication failure. The missed doses and high baseline delta over baseline-value were important contributors in men and women (all Ptrend<0.001). However, a dose-response relationship between failure rate and smoking or drinking index was found in men (all Ptrend<0.001), while high body mass index (Ptrend<0.001) and history of stomach disease were significant predictors in women. The treatment failure rate increased up to 48.8% (OR 2.87, 95% CI 2.24 to 3.68) in men and 39.4% (OR 2.67, 95% CI 1.61 to 4.42) in women with multiple factors combined. CONCLUSIONS: This large community-based intervention trial to eradicate H. pylori is feasible and acceptable. The findings of this trial lead to a distinct evaluation of factors influencing eradication that should be generally considered for future eradication therapies. TRIAL REGISTRATION NUMBER: ChiCTR-TRC-10000979 in accordance with WHO ICTRP requirements.
Healthy Bureau of Linqu County Weifang China
Institute of Pathology Klinikum Bayreuth Bayreuth Germany
Technische Universität München Munich Germany
Technische Universität München Munich Germany International Digestive Cancer Alliance Germany
Citace poskytuje Crossref.org
Advances in the Aetiology & Endoscopic Detection and Management of Early Gastric Cancer
ChiCTR
CHICTR-TRC-10000979
